Skip to main content

Table 1 Patient characteristics

From: Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

Characteristics Number of patients n = 36, n (%)
Age (years)
 Median 54
 Range (15–79)
Gender
 Male 14 (39%)
 Female 22 (61%)
Race
 White/Caucasian 28 (78%)
 Black/African-America 4 (11%)
 Other 4 (11%)
Smoking
 Active or history of smoking 18 (50%)
 Never smoker 18 (50%)
ECOG performance status
 0 1 (3%)
 1 30 (83%)
 2 5 (14%)
Tumor type
 Head and neck squamous cell carcinoma 10 (28%)
 Cervical cancer 10 (28%)
 Thyroid follicular carcinoma 4 (11%)
 Breast cancer 3 (8%)
 Pancreatic cancer 3 (8%)
 Salivary glands cancer 2 (6%)
 Bladder urothelial carcinoma 2 (6%)
 Sarcoma 1 (3%)
 Vulvar cancer 1 (3%)
 Squamous cell carcinoma of the skin 1 (3%)
Number of prior systemic therapies
 Median 3
 Range 1–10
Prior systemic treatment with anti-EGFR 8 (22%)
Prior systemic treatment with anti-VEGF 9 (25%)
Prior systemic treatment with anti-EGFR and anti-VEGF (sequential) 2 (6%)